Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 743

Showing 51-75 of 743 citing articles:

What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 103
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 85
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S145-S157
Open Access | Times Cited: 85
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
Anders Boisen Jensen, Frida Renström, Stefan Aczél, et al.
Obesity Surgery (2023) Vol. 33, Iss. 4, pp. 1017-1025
Open Access | Times Cited: 84
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 78
The Related Metabolic Diseases and Treatments of Obesity
Ming Yang, Shuai Liu, Chunye Zhang
Healthcare (2022) Vol. 10, Iss. 9, pp. 1616-1616
Open Access | Times Cited: 75
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Ildiko Lingvay, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
Obesity (2022) Vol. 31, Iss. 1, pp. 111-122
Open Access | Times Cited: 73
Obesity in South and Southeast Asia—A new consensus on care and management
Kwang Wei Tham, Rohana Abdul Ghani, C. Sioksoan, et al.
Obesity Reviews (2022) Vol. 24, Iss. 2
Open Access | Times Cited: 71
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Vanita R. Aroda, Jens Aberle, Lars Bardtrum, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 693-704
Open Access | Times Cited: 61
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 59
Obesity and diabetes
Chrysoula Boutari, Antea DeMarsilis, Christos S. Mantzoros
Diabetes Research and Clinical Practice (2023) Vol. 202, pp. 110773-110773
Closed Access | Times Cited: 56
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Femin Prasad, Riddhita De, Vittal Korann, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 54
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 54
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden, Ariana M. Chao, Molly Moore, et al.
Current Obesity Reports (2023) Vol. 12, Iss. 4, pp. 453-473
Open Access | Times Cited: 54
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, et al.
Diabetes Care (2023) Vol. 46, Iss. 4, pp. 801-810
Open Access | Times Cited: 52
Obesity in adults
Ildiko Lingvay, Ricardo V. Cohen, Carel W. le Roux, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 972-987
Closed Access | Times Cited: 52
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 8, pp. 1000-1010
Open Access | Times Cited: 51
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, et al.
Diabetes Care (2024) Vol. 48, Iss. Supplement_1, pp. S181-S206
Closed Access | Times Cited: 51
Sarcopenic obesity in older adults: a clinical overview
Carla M. Prado, John A. Batsis, Lorenzo M. Donini, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 5, pp. 261-277
Closed Access | Times Cited: 50
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal, Lee M. Kaplan, Juan P. Frías, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2037-2048
Open Access | Times Cited: 49
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 48
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi, Yang Wang, Qiukui Hao, et al.
The Lancet (2024) Vol. 403, Iss. 10434, pp. e21-e31
Closed Access | Times Cited: 46
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Patricia J. Rodriguez, Brianna M. Goodwin Cartwright, Samuel Gratzl, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 9, pp. 1056-1056
Open Access | Times Cited: 42
Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 40

Scroll to top